- The ready-to-use pre-filled syringe combines two well-known,
FDA-approved products in a standard concentration ratio
- Product eliminates the need for two discrete syringe
preparations and administrations, which helps increase efficiency
for hospitals and healthcare providers
DUBLIN, June 12, 2023 /PRNewswire/ -- Endo International
plc (OTC: ENDPQ) announced today that its Par Sterile Products
business has begun shipping PREVDUO™ (neostigmine
methylsulfate and glycopyrrolate injection) pre-filled syringe, the
first and only FDA-approved neostigmine–glycopyrrolate combination
product in the U.S.
"This is the latest way we're addressing operational and
clinical challenges in order to support patient care," said
Scott Sims, Senior Vice President
and General Manager, Injectable Solutions & Generics at Endo.
"With two medications in one ready-to-use syringe,
PREVDUO™ reduces complexity and increases
efficiency for hospitals and healthcare providers."
Both neostigmine methylsulfate and glycopyrrolate have been
approved in the U.S. as single, active ingredient drug products.
Neostigmine is always administered in conjunction with
glycopyrrolate and, until now, its administration has required two
syringes.
In April, Endo executed an agreement with Slayback Pharma LLC to
distribute PREVDUO™ on an exclusive basis in the
U.S.
Ready-to-use, or RTU, products streamline operations for
hospitals by eliminating the need to prepare or transfer the
product before patient administration. This may reduce waste and
costs, optimize convenience and workflow and reduce the chance for
preparation error—all of which support quality patient care.
About Endo
Endo (OTC: ENDPQ) is a specialty pharmaceutical company
committed to helping everyone we serve live their best life through
the delivery of quality, life-enhancing therapies. Our decades of
proven success come from passionate team members around the globe
collaborating to bring treatments forward. Together, we boldly
transform insights into treatments benefiting those who need them,
when they need them. Learn more at www.endo.com or connect
with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation including, but not limited to, the
statements by Mr. Sims, any statements relating to product launch,
commercialization, sales, supply or distribution, and any
statements that refer to expected, estimated or anticipated future
results or that do not relate solely to historical facts.
Statements including words or phrases such as "believe," "expect,"
"anticipate," "intend," "estimate," "plan," "will," "may," "look
forward," "intend," "guidance," "future," "potential" or similar
expressions are forward-looking statements. All forward-looking
statements in this communication reflect the Company's current
views as of the date of this communication about its plans,
intentions, expectations, strategies and prospects, which are based
on the information currently available to it and on assumptions it
has made. Actual results may differ materially and adversely from
current expectations based on a number of factors, including, among
other things, the outcome of the Company's contingency planning and
restructuring activities; the timing, impact or results of any
pending or future litigation, investigations, proceedings or
claims, including opioid, tax and antitrust related matters; any
actual or contingent liabilities; settlement discussions or
negotiations; the Company's liquidity, financial performance, cash
position and operations; the risks and uncertainties associated
with chapter 11 proceedings; the time, terms and ability to confirm
a sale of the Company's businesses under Section 363 of the U.S.
Bankruptcy Code; the risk that the Company's chapter 11 cases may
be converted to cases under chapter 7 of the Bankruptcy Code; the
adequacy of the capital resources of the Company's businesses and
the difficulty in forecasting the liquidity requirements of the
operations of the Company's businesses; the unpredictability of the
Company's financial results; the Company's ability to discharge
claims in chapter 11 proceedings; negotiations with the holders of
the Company's indebtedness and its trade creditors and other
significant creditors; the risks and uncertainties with performing
under the terms of the restructuring support agreement and any
other arrangement with lenders or creditors while in chapter 11
proceedings; the performance, including the approval, introduction,
and consumer and physician acceptance of new products and the
continuing acceptance of currently marketed products; and the
Company's ability to obtain and successfully manufacture, maintain
and distribute a sufficient supply of products to meet market
demand in a timely manner. The Company expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required to do so by law.
Additional information concerning risk factors, including those
referenced above, can be found in press releases issued by the
Company, as well as the Company's public periodic filings with the
U.S. Securities and Exchange Commission and with securities
regulators in Canada, including
the discussion under the heading "Risk Factors" in the Company's
most recent Annual Report on Form 10-K and any subsequent Quarterly
Reports on Form 10-Q or other filings with the U.S. Securities and
Exchange Commission.
Logo -
https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/endo-launches-prevduo-neostigmine-methylsulfate-and-glycopyrrolate-injection-the-first-and-only-fda-approved-neostigmineglycopyrrolate-combination-pre-filled-syringe-301847835.html